Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Y-mAbs Therapeutics Inc.

http://www.ymabs.com/

Latest From Y-mAbs Therapeutics Inc.

Finance Watch: Sun Shines On Biotech Stocks As J.P. Morgan Ends

Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.

Financing Restructuring

Rare Disease Patients: Placebo Controls, Sham Surgeries Not Appropriate For Gene Therapy Trials

Advocates also worry that long follow-up times could prevent participation in future clinical trials.

Clinical Trials Gene Therapy

Etranacogene Dezaparvovec, Omburtamab & Tremelimumab Await EMA Verdict

Four of the six products up for a marketing authorization opinion from the EMA’s advisory committee, the CHMP, this week are orphan drugs. One of them, omburtamab, was recently turned down by a US FDA advisory panel.

Europe Approvals

Y-mAbs Shifts Focus To Approved Drug, Pipeline After Omburtamab CRL

The FDA’s thumbs-down was largely expected after a negative advisory committee review and the path forward for the drug remains unclear – but the company is prioritizing other programs.

Complete Response Letters ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Y-mAbs Therapeutics A/S
UsernamePublicRestriction

Register